News Archive: August 2026

All peptide regulatory news from August 2026.

31 Articles in August 2026

Enforcement Actions August 10, 2026

TGA Fines for Importing Peptides to Australia: 2024-2025 Complete Guide

Overview of the Regulatory Action Australia's Therapeutic Goods Administration (TGA) has intensified scrutiny of research peptides such as BPC-157, TB-500, CJC-1295, and Ipamorelin, treating their importation for human use as a violation of the Therapeutic Goods Act 1989 (Cth).

Legal Analysis August 10, 2026

Australian TGA Personal Importation Scheme: Can You Legally Import Peptides?

Australian TGA Personal Importation Scheme: Can You Legally Import Peptides? Australians seeking to import research peptides and growth hormone secretagogues for personal use face a significant legal obstacle: the Therapeutic Goods Administration's (TGA) Personal Importation Scheme, widely believed...

Industry News August 10, 2026

Growth Hormone Secretagogues Australia: TGA Classification and Legal Status

Growth Hormone Secretagogues in Australia: Prescription-Only Status Carries Serious Legal Risk for Unauthorized Importation Australians seeking growth hormone secretagogues such as Ipamorelin, CJC-1295, GHRP-2, GHRP-6, Sermorelin, and MK-677 (Ibutamoren) face a strict regulatory environment that cl...

Enforcement Actions August 10, 2026

Australian Border Force Peptide Seizures: What Happens When Your Package is Stopped

Australian Border Force Peptide Seizures: What Happens When Your Package is Stopped Australians ordering peptides online are increasingly encountering a hard truth at the border: packages containing these substances are being flagged, held, and in many cases seized by Australian Border Force (ABF) ...

Legal Analysis August 10, 2026

BPC-157 Legal Status in Australia: TGA Regulations Explained

Overview of the Regulatory Action BPC-157, a synthetic peptide derived from a fragment of a protein found in human gastric juice, has become one of the most searched-for compounds in the peptide and performance-enhancement communities worldwide.

Federal Regulations August 10, 2026

Are Peptides Illegal in California? State Laws Explained

Are Peptides Illegal in California? What the Current Rules Actually Say Confusion over the legal status of therapeutic peptides — from BPC-157 to CJC-1295 and semaglutide-adjacent compounds — has intensified as more Californians turn to wellness clinics, telehealth providers, and compounding ph...

State Laws August 10, 2026

California Peptide Therapy Laws: What Doctors and Patients Need to Know

California Peptide Therapy Laws: What Doctors and Patients Need to Know Disclaimer: This article summarizes general regulatory frameworks governing peptide therapy in California. It is intended as background information for healthcare providers and patients, not as legal or medical advice.

Federal Regulations August 10, 2026

Texas Peptide Laws 2024: Regulations for BPC-157, TB-500, and More

Texas Peptide Laws 2024: What Residents and Businesses Need to Know About BPC-157, TB-500, and Compounded Peptide Therapies As interest in peptide therapies such as BPC-157 and TB-500 continues to grow among Texas consumers, wellness clinics, and compounding pharmacies, questions about the state's ...

State Laws August 10, 2026

Florida Peptide Regulations: State Law Guide for 2024

Florida Peptide Regulations: What Compounders, Clinics, and Consumers Need to Know Peptide therapies—ranging from BPC-157 to semaglutide analogs sold outside FDA-approved branded products—have become a flashpoint for state and federal regulators. Florida is no exception.

Federal Regulations August 10, 2026

FDA panel supports broadening access to peptides popular on the gray market

FDA Advisory Panel Signals Openness to Expanding Legal Access to Popular Peptide Compounds A Food and Drug Administration advisory panel has expressed support for broadening legitimate access to certain peptide compounds that have gained significant popularity through gray-market channels, accordin...

Federal Regulations August 10, 2026

How the FDA Regulates Peptides

How the FDA Regulates Peptides: A Growing Regulatory Gray Zone Under Scrutiny The Food and Drug Administration's oversight of peptide-based products has come under renewed examination, as a new analysis from the Johns Hopkins Bloomberg School of Public Health lays out the complex and often confusin...

Federal Regulations August 10, 2026

FDA staff and peptide enthusiasts set to clash at advisory panel

FDA Advisory Panel Set to Weigh In on Contested Peptide Compounds Amid Growing Industry Tension A forthcoming Food and Drug Administration advisory committee meeting is expected to become a flashpoint in the ongoing debate over the regulatory status of popular research and wellness peptides, accord...

Industry News August 10, 2026

F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

California Pharmacy Regulators Weigh Response to Federal Peptide Prescribing Debate A recent advisory panel vote at the U.S.

Federal Regulations August 10, 2026

FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype

FDA's Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype A recent Forbes report has drawn renewed attention to the Food and Drug Administration's ongoing scrutiny of the peptide industry, highlighting what the publication frames as a growing public health ch...

Industry News August 10, 2026

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

Novo Nordisk Prevails in Netherlands Legal Battle Over Compounded GLP-1 Products Novo Nordisk has secured a legal victory in the Netherlands in a lawsuit concerning compounded versions of its GLP-1 receptor agonist medications, according to a report from pharmaphorum.

Industry News August 10, 2026

Troubling Findings in Study of GLP-1 Compounders

Troubling Findings in Study of GLP-1 Compounders A new study examining compounded versions of popular GLP-1 receptor agonist drugs has surfaced concerning findings, according to a report from MedPage Today, adding fresh scrutiny to an industry that expanded rapidly during a nationwide shortage of b...

Federal Regulations August 10, 2026

FDA panel backs 6 peptides despite its own scientists’ objections

FDA Panel Backs Six Peptides Despite Internal Scientific Objections A Food and Drug Administration advisory panel has voted to support the use of six peptide compounds for compounding, moving forward despite documented objections from the agency's own scientific staff, according to a report from Ma...

Industry News August 10, 2026

August 3, 2026: Peptide vendor sentenced to six years for “incredible trail of harm”

Peptide Vendor Sentenced to Six Years in Federal Case Highlighting Dangers of Unregulated Peptide Market A peptide vendor has been sentenced to six years in federal prison following a prosecution that a federal judge reportedly described as leaving behind an "incredible trail of harm," according to...

Federal Regulations August 10, 2026

FDA puts former Rancho Santa Fe pharmacist on notice for selling unapproved weight-loss injections online

FDA Targets Former Rancho Santa Fe Pharmacist Over Online Weight-Loss Injection Sales The U.S.

Federal Regulations August 10, 2026

July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list

FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding a group of unapproved peptide drugs to the agency's compounding list, according to reporting from the Partnership fo...

Industry News August 10, 2026

The five risks of taking unapproved peptides

Partnership for Safe Medicines Report Highlights Growing Dangers in Unregulated Peptide Market The Partnership for Safe Medicines, a nonprofit coalition focused on drug safety and public health, has published a report identifying five key risks associated with the use of unapproved peptides — a r...

Federal Regulations August 10, 2026

FDA advisers back first four of seven unapproved peptides under review for looser rules

FDA Advisory Panel Recommends Looser Rules for Four Unapproved Peptides, With Three More Under Review A Food and Drug Administration advisory committee has voted to support looser regulatory treatment for four of seven unapproved peptide compounds currently under agency review, according to a repor...

Industry News August 10, 2026

Peptides May Soon Be Legal. These Companies Are Ready To Cash In

Peptides May Soon Be Legal: Industry Players Position Themselves Ahead of Potential Regulatory Shift A new report from Forbes signals that the regulatory landscape for peptide-based products may be on the verge of significant change, with companies across the supplement, wellness, and pharmaceutica...

Federal Regulations August 10, 2026

FDA panel to review popular peptides amid persistent consumer appetite

FDA Panel to Review Popular Peptides Amid Persistent Consumer Appetite The U.S.

Federal Regulations August 10, 2026

FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists

FDA Advisory Panel Backs Expanded Peptide Compounding Over Objections From Agency's Own Scientists A Food and Drug Administration advisory panel has voted to recommend adding certain peptides to the list of substances that compounding pharmacies are permitted to use, a decision reached despite push...

Federal Regulations August 10, 2026

FDA panel votes to loosen restrictions for controversial peptides

FDA Advisory Panel Votes to Ease Restrictions on Controversial Peptide Compounds A Food and Drug Administration advisory panel has voted to loosen restrictions on a category of peptide compounds that have been at the center of an ongoing regulatory debate, according to a report from the BBC.

Federal Regulations August 10, 2026

An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition

FDA Advisory Panel Breaks With Agency Staff, Backs Continued Access to Peptide Compounds A Food and Drug Administration advisory committee has voted in favor of preserving broader access to certain peptide-based compounds, setting up a notable clash with the agency's own staff recommendations, acco...

Federal Regulations August 10, 2026

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

FDA Panel to Revisit Biden-Era Peptide Restrictions Amid Push for Regulatory Flexibility A Food and Drug Administration advisory panel is preparing to reexamine restrictions placed on a category of therapeutic peptides during the Biden administration, according to a report from Bloomberg Law News.

Industry News August 10, 2026

How wellness clinics bend the rules to supply unapproved peptides and anti-ageing injections

Wellness Clinics Skirt Regulatory Barriers to Sell Unapproved Peptides and Anti-Ageing Injections A growing network of wellness clinics across the country is exploiting regulatory loopholes to market and administer unapproved peptide therapies and anti-ageing injections, according to reporting from...

Federal Regulations August 10, 2026

Compounded GLP-1s: Why doctors worry and the FDA is cracking down

Compounded GLP-1s: Why Doctors Worry and the FDA Is Cracking Down The explosive popularity of GLP-1 receptor agonists like semaglutide and tirzepatide for weight loss and diabetes management has spawned a booming secondary market: compounded versions of these drugs, sold at a fraction of brand-name...

Federal Regulations August 10, 2026

Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides

Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides As federal oversight of compounded GLP-1 medications and research peptides continues to evolve at the U.S.